Clinical trials: Acute Cardiac Failure
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Heart Decompensation, Congestive Heart Failure
An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart Failure
The present study was an open-label, uncontrolled, and multi-centered phase III clinical trial for evaluation of the efficacy (clinical efficacy and hemodynamics) and safety of nesiritide.
- Trial name
- NCT00813202
- Testing
- Nesiritide
- Where
- 4 sites in China
- Volunteers
- 41 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Acute Decompensated Heart Failure
Cardionomic STOP-ADHF Study
STOP-ADHF Study: An evaluation of the safety and performance of the Cardionomic Cardiac Pulmonary Nerve Stimulation (CPNS) system in patients with acute decompensated heart failure.
- Trial name
- NCT04814134
- Testing
- CPNS Therapy, Standard of care
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 59 people
- Sponsor
- Cardionomic Inc.
Acute Heart Failure
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE 1 (NCT01065077)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 59 sites in United States, Austria and 15 more
- Volunteers
- 12 people
- Sponsor
- Bayer
Acute Heart Failure With Reduced Ejection Fraction
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05139615
- Testing
- APD418
- Where
- 21 sites in United States, Germany and 3 more
- Volunteers
- 22 people
- Sponsor
- Pfizer
Acute MI, Heart Failure
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and…
- Conditions
- Acute MI, Heart Failure, Diabetes Mellitus, Kidney Disease
- Trial name
- CHAPERONE-CKM (NCT07403669)
- Testing
- CHAPERONE AI, CKMiq AI, Quality of Life
- Where
- 5 sites in United States, Sweden
- Volunteers
- 300 people
- Sponsor
- Aventyn, Inc.
Myocardial Infarction
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart…
- Trial name
- NCT04509674
- Testing
- Empagliflozin
- Where
- 439 sites in United States, Argentina and 20 more
- Volunteers
- 6,522 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Left Bundle-Branch Block
LV Only MPP With SyncAV
The objective of this clinical investigation is to evaluate the clinical benefits of left ventricle (LV) only pacing combined with automatic adjustment of AV timing (SyncAV) in patients receiving cardiac resynchronization therapy…
- Trial name
- NCT03567096
- Testing
- BiV pacing with MPP and SyncAV, LV only pacing with MPP and SyncAV
- Where
- 6 sites in Canada, France and 2 more
- Volunteers
- 101 people
- Sponsor
- Abbott Medical Devices
Acute Heart Failure
Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure
This study will assess the hemodynamic effect of RLX030 infusion in subjects with acute heart failure. In addition safety and effects on renal function and biomarkers will be assessed.
- Trial name
- NCT01543854
- Testing
- RLX030
- Where
- 20 sites in Argentina, Germany and 4 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Cardiogenic Shock, Acute Decompensated Heart Failure
SURPASS Impella 5.5 Study
A multi-center, prospective \& retrospective, observational single-arm study of the clinical outcomes up to one year collected from electronic health records of patients which have undergone standard of care implantation of…
- Trial name
- NCT05100836
- Testing
- Impella 5.5
- Where
- 15 sites in United States
- Volunteers
- 1,017 people
- Sponsor
- Abiomed Inc.
Dyspnea,, Acute Heart Failure Syndrome
Fluid Status of Outpatients With Dyspnea
The purpose of this study is to determine the distribution of lung fluid status as reported by the IMED-4 system in patients presenting to the emergency department or urgent care facility with shortness of breath.
- Conditions
- Dyspnea,, Acute Heart Failure Syndrome, Pulmonary Congestion
- Trial name
- FLOOD (NCT02111525)
- Where
- 2 sites in United States
- Volunteers
- 156 people
- Sponsor
- Intersection Medical, Inc.
Acute Myocardial Infarction, Heart Failure
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF)…
- Trial name
- DAPA-MI (NCT04564742)
- Testing
- Dapagliflozin
- Where
- 103 sites in Sweden, United Kingdom
- Volunteers
- 4,017 people
- Sponsor
- AstraZeneca
Acute Heart Failure
A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure
The purpose of this study is to evaluate the efficacy and safety of Shenfu Zhusheye in patients with acute heart failure.
- Trial name
- NCT02135835
- Testing
- Shenfu Zhusheye, 5% glucose injection
- Where
- 25 sites in China
- Volunteers
- 365 people
- Sponsor
- China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Heart Failure With Preserved Ejection Fraction (HFpEF)
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who had been stabilized and initiated at the time of or within 30 days…
- Trial name
- PARAGLIDE-HF (NCT03988634)
- Testing
- sacubitril/valsartan, valsartan
- Where
- 97 sites in United States, Canada
- Volunteers
- 467 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Reduced Ejection Fraction
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection…
- Trial name
- AWAKE-HF (NCT02970669)
- Testing
- sacubitril/valsartan (LCZ696), enalapril
- Where
- 23 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Voice Analysis for Monitoring Patients With Heart Failure
This observational study involves ADHF patients at two sites in the United States and Germany. After informed consent and screening assessments, participants will perform daily voice recordings during their hospital stay, from…
- Trial name
- VAMP-HF (NCT06566911)
- Where
- 2 sites in United States, Germany
- Volunteers
- 70 people
- Sponsor
- Noah Labs
Myocardial Infarction
Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction
The purpose of the study is to determine whether adult stem cells [Provacel™(PUMP1)] are safe and possibly effective in the treatment of acute myocardial infarction (heart attack).
- Trial name
- NCT00114452
- Testing
- Provacel
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mesoblast, Inc.
Heart Failure, Acute Heart Failure
PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure
This study evaluates whether tailored, peripheral ultrafiltration complementary to low-dose diuretics is associated with a reduction in cardiovascular mortality in 90 days after randomization and heart failure events in 90 days…
- Trial name
- NCT03161158
- Testing
- CHIARA-System, Usual care IV diuretics
- Where
- 11 sites in Germany, Sweden
- Volunteers
- 62 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Severe Dyspnea, CAPD
BIOmarkers of Dyspnea IN Emergency Room
The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine…
- Conditions
- Severe Dyspnea, CAPD, AE COPD, Acute Heart Failure
- Trial name
- BIODINER (NCT01227317)
- Testing
- Prognostic value of Biomarkers
- Where
- France
- Volunteers
- 444 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France